<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01952288</url>
  </required_header>
  <id_info>
    <org_study_id>B1195-I</org_study_id>
    <nct_id>NCT01952288</nct_id>
  </id_info>
  <brief_title>Simvastatin for mTBI</brief_title>
  <official_title>Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of simvastatin in Iraq/Afghanistan Veterans with multiple blast exposure and mTBI. The&#xD;
      study will measure substances in cerebrospinal fluid (CSF) that are related to dementing&#xD;
      disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many Iraq and Afghanistan Veterans have experienced repetitive blast exposure mild traumatic&#xD;
      brain injury (mTBI) with persistent cognitive, emotional, and neurological postconcussive&#xD;
      symptoms. There is an urgent need to develop effective treatments to reduce both the&#xD;
      intensity of these Veterans' current symptoms as well as their potential long-term risks for&#xD;
      developing neurodegenerative dementing disorders related to repetitive mTBI: chronic&#xD;
      traumatic encephalopathy (CTE) and Alzheimer's disease (AD). Converging evidence suggests&#xD;
      that statins may possess neuroprotective effects against pathologic processes related to tau&#xD;
      protein metabolism that appear to be a common feature of CTE, AD, and other neurodegenerative&#xD;
      sequelae of repetitive mTBI.&#xD;
&#xD;
      The investigators propose a 12-month, double-blind, randomized, active-drug-controlled trial&#xD;
      to establish proof-of-concept for use of simvastatin (40 mg/d) for decreasing CSF biomarkers&#xD;
      of neurodegeneration and increasing CSF neurotrophins in 120 Iraq and Afghanistan Veterans&#xD;
      with repetitive blast trauma mTBI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2013</start_date>
  <completion_date type="Actual">June 20, 2017</completion_date>
  <primary_completion_date type="Actual">June 20, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cerebrospinal fluid (CSF) tau concentration</measure>
    <time_frame>baseline, 12 months post-treatment</time_frame>
    <description>Change in CSF tau concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of cerebrospinal fluid (CSF) Brain-derived neurotrophic factor (BDNF)</measure>
    <time_frame>Baseline, 12 months post-treatment</time_frame>
    <description>Change in CSF BDNF concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>TBI-Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>simvastatin 40 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>simvastatin 40 mg/day for 12 months</description>
    <arm_group_label>simvastatin</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>placebo comparator</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females ages 21-50 years.&#xD;
&#xD;
          -  Documented hazardous duty in Iraq and or Afghanistan with the U.S. Armed Forces.&#xD;
&#xD;
          -  Exposure to one or more blast trauma events resulting in mTBI according to American&#xD;
             Congress of Rehabilitation Medicine (ACRM) criteria.&#xD;
&#xD;
          -  More than 6 months since last blast trauma exposure&#xD;
&#xD;
          -  Ability to complete psychometric and other clinical assessments in English (i.e.,&#xD;
             adequate English language skills, vision and hearing).&#xD;
&#xD;
          -  elevated cholesterol levels, i.e. total cholesterol &gt;200 and/or LDL &gt;130. This would&#xD;
             generally prompt the initiation of a lipid-lowering agent as standard care in the&#xD;
             general medical community.&#xD;
&#xD;
          -  No use of statins during the previous year and no recent (past 4 weeks) use of other&#xD;
             lipid-lowering drugs (e.g., fibrates, niacin &gt; 500mg/d, or high dose omega-3 fatty&#xD;
             acids) preceding randomization.&#xD;
&#xD;
          -  No clinically significant laboratory abnormalities (electrolytes, glucose, carbon&#xD;
             dioxide, blood urea nitrogen (BUN), creatinine, vitamin B12, folate, albumin, thyroid&#xD;
             stimulating hormone).&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm2.&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18 and 36 inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of head trauma with loss of consciousness (LOC)&gt;30 minutes, or with a&#xD;
             penetrating head wound, or with moderate to severe memory or other cognitive&#xD;
             impairment.&#xD;
&#xD;
          -  Neurological disorders: multiple sclerosis, epilepsy, stroke, Parkinson's disease&#xD;
             (PD), other degenerative Central Nervous System (CNS) disorders, or neuropathy with&#xD;
             radicular involvement.&#xD;
&#xD;
          -  Acute or chronic major psychiatric disorders: schizophrenia, bipolar disorder or&#xD;
             severe major depressive disorder, or severe anxiety disorder except PTSD and panic&#xD;
             disorder (PTSD and depressive symptoms are common co-morbid conditions for combat mTBI&#xD;
             and a subset of these patients have symptoms consistent with panic disorder as well).&#xD;
&#xD;
          -  Use of illegal drugs; alcohol abuse within the past 6 months.&#xD;
&#xD;
          -  Poorly controlled hypertension, heart failure, coronary heart disease, peripheral&#xD;
             artery disease, carotid artery disease, diabetes mellitus, pulmonary disease with&#xD;
             hypoxia or hypercapnia, significant hepatic disease or hepatitis C seropositivity,&#xD;
             renal failure, treatment for cancer, HIV positive, active infectious disease or&#xD;
             presence of abdominal aortic aneurysm.&#xD;
&#xD;
          -  Contraindications to lumbar puncture (LP) (e.g., spinal cord injury; deformity, severe&#xD;
             disease or infection in the region of the lumbosacral spine; bleeding tendency, use of&#xD;
             anticoagulant medications, or platelet count &lt;100,000/mm2).&#xD;
&#xD;
          -  Receiving medication in an investigational drug study.&#xD;
&#xD;
          -  Exclusionary medications (used in the 4 weeks prior to screening):&#xD;
&#xD;
          -  Fibrates and niacin due to increased risk for myopathy in combination with statins;&#xD;
&#xD;
          -  Potential drug-drug interactions with statins via effects on CYP3A4: itraconazole,&#xD;
             ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, nefazodone,&#xD;
             amiodarone, cyclosporine, isoniazid, quinidine, or large quantities of grapefruit&#xD;
             juice (&gt;1 quart daily);&#xD;
&#xD;
          -  Selected CNS-acting medications: antipsychotics, anti-Parkinson's disease medications&#xD;
             and CNS stimulants&#xD;
&#xD;
          -  Other medications affecting coagulation and/or inflammation: coumadin, potent&#xD;
             anti-inflammatory medications (hydrocortisone, methotrexate or other potent&#xD;
             immune-modulating medications), and anti-HIV medications.&#xD;
&#xD;
          -  All female subjects of childbearing potential will undergo a urine pregnancy test at&#xD;
             every subject visit; subjects with positive pregnancy test results will be excluded.&#xD;
             In addition, all female subjects of childbearing potential will be required to use a&#xD;
             reliable method of contraception throughout the duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine R Peskind, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Puget Sound Health Care System Seattle Division, Seattle, WA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System Seattle Division, Seattle, WA</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers JJ, Montine TJ, Lee VM, Lee M, Seubert P, Galasko D, Schellenberg GD, Hazzard WR, Peskind ER. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis. 2006 Dec;10(4):399-406.</citation>
    <PMID>17183151</PMID>
  </reference>
  <reference>
    <citation>Li G, Mayer CL, Morelli D, Millard SP, Raskind WH, Petrie EC, Cherrier M, Fagan AM, Raskind MA, Peskind ER. Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults. Neurology. 2017 Sep 19;89(12):1251-1255. doi: 10.1212/WNL.0000000000004392. Epub 2017 Aug 18.</citation>
    <PMID>28821686</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2013</study_first_posted>
  <disposition_first_submitted>June 22, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>June 22, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 29, 2018</disposition_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 17, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

